Clinical Efficacy of Combination Therapy Based on High-dose Biapenem in CRKP Infections
NCT ID: NCT04552444
Last Updated: 2020-09-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
200 participants
OBSERVATIONAL
2019-06-01
2021-08-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Outcomes of Hypervirulent Carbapenem-resistant Klebsiella Pneumoniae Infection
NCT06190548
Epidemiological Characteristics and Treatment Protocol for Carbapenem-Resistant Klebsiella Pneumoniae in China
NCT03245632
The Combined Antibiotic Therapy for Carbapenem Resistant Klebsiella Pneumoniae
NCT03950544
Epidemiology of Klebsiella Pneumoniae in China
NCT03598543
Double Carbapenem as Rescue Strategy for the Treatment of Carbapenemase-Producing Klebsiella Pneumoniae Infections
NCT03094494
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
the death group
Through the corresponding treatment, the patients who died within 28 days
Biapenem
In the course of CRKP treatment, double dose biapenem was selected.
the survival group
Through the corresponding treatment, the patients who survived within 28 days
Biapenem
In the course of CRKP treatment, double dose biapenem was selected.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Biapenem
In the course of CRKP treatment, double dose biapenem was selected.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Biapenem used for more than 3 days
Exclusion Criteria
14 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Second Affiliated Hospital, School of Medicine, Zhejiang University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Man Huang, Ph.D
Sponsor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Second Affiliated Hospital of Zhejiang University Medical College
Hangzhou, Please Select, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SAHZU2017087
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.